Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

AbbVie Inc. researches and develops pharmaceutical products. The Company produces pharmaceutical drugs for specialty therapeutic areas such as immunology, chronic kidney disease, hepatitis C, women"s health, oncology, and neuroscience. AbbVie also offers treatments for diseases including multiple sclerosis, parkinson"s, and alzheimer"s disease.
Website: abbvie.com


  • Bad financial results growth rate -19.4% (average between last period year over year growth for revenue and EBITDA), there is slowdown compared to average historical growth rates (-9.8%)
  • Dividend yield for the last twelve months 2.9%
  • Free cash flow yield 0.2% (LTM)
  • Share price is 73.6% higher than minimum and 5.9% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (48.0x vs
    )
  • Fundamental value created in LTM (estimate)

Key Financials (Download financials)

Ticker: ABBV
Share price, USD:  (0.0%)229.98
year average price 203.82  


year start price 175.17 2025-01-10

min close price 169.20 2025-01-22

max close price 244.38 2025-10-01

current price 229.98 2026-01-10
Common stocks: 1 768 480 508

Dividend Yield:  2.9%
FCF Yield LTM: 0.2%
EV / LTM EBITDA: 48.0x
EV / EBITDA annualized: 56.0x
Last revenue growth (y/y):  +9.1%
Last growth of EBITDA (y/y):  -47.9%
Historical revenue growth:  +1.2%
Historical growth of EBITDA:  -20.9%
Target EV / EBITDA (hist percentile):
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 406 715
Net Debt ($m): 63 115
EV (Enterprise Value): 469 830
EBITDA LTM ($m): 9 787
EV / LTM EBITDA: 48.0x
Price to Book: -153.5x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2026-01-04seekingalpha.com

AbbVie: Rocky Near-Term, Positive Long-Term

2026-01-03seekingalpha.com

My Most Important Warning To Dividend Investors For 2026

2026-01-03fool.com

Buying This Healthcare Stock Could Make You a Millionaire Retiree

2026-01-02zacks.com

Here's How AbbVie's Neuroscience Portfolio Is Aiding Top-line Growth

2026-01-01seekingalpha.com

AbbVie: Solid Growth, Some Risks, And An Attractive Setup In 2026

2025-12-31seekingalpha.com

Best Dividend Aristocrats For January 2026

2025-12-30fool.com

3 No-Brainer Dividend Stocks to Buy Right Now

2025-12-30zacks.com

3 Dividend-Paying Pharma Stocks Worth Watching for Steady 2026 Gains

2025-12-28seekingalpha.com

Best Dividend Kings: December 2025

2025-12-27fool.com

2 Dividend Stocks to Double Up On Right Now
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data